Evidence map›Paper›PMID 26674525›Full record

ArticlePloS one2015

Serum LncRNAs Profiles Serve as Novel Potential Biomarkers for the Diagnosis of HBV-Positive Hepatocellular Carcinoma.

Kang Wang, Wei Xing Guo, Nan Li, Chun Fang Gao, Jie Shi, Yu Fu Tang, Feng Shen, Meng Chao Wu, Shan Rong Liu, Shu Qun Cheng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 6 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 6 syntheses or guidelines pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Combinatorial Gene Expression Profiling of SerumInternational journal of molecular sciences · 2024
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Long noncoding RNAs as novel serum biomarkers for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017
    Pooled it
  6. Pooled it
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Kang WangEastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China.
Wei Xing GuoEastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China.
Nan LiEastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China.
Chun Fang GaoEastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China.
Jie ShiEastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China.
Yu Fu TangEastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China.
Feng ShenEastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China.
Meng Chao WuEastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China.
Shan Rong LiuChanghai Hospital, the Second Military Medical University, Shanghai, China.
Shu Qun ChengEastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China.
Second Military Medical University · CNEastern Hepatobiliary Surgery Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is a common malignancy that has a poor prognosis because there is lack of methods for early diagnosis. We aimed to utilize two serum long non-coding RNAs (lncRNAs), uc001ncr and AX800134, to diagnose hepatitis B virus (HBV)-positive HCC.

methodslncRNA microarrays were utilized to measure the differential expression of lncRNAs between tumor tissues and corresponding non-tumor tissues in HBV-positive hapatocellular carcinoma. uc001ncr and AX800134 were selected as candidate lncRNAs and detected in three independent cohorts containing a total of 684 participants (healthy individuals and chronic HBV patients and HBV-positive HCC patients) who were recruited between March 2011 and December 2012. A logistic regression model was constructed using a training cohort (n = 353) and validated using an independent cohort (n = 181). The area under the receiver operating characteristic curve (AUC) was utilized to evaluate the diagnostic accuracy.

resultsWe determined that a panel based on the expression of uc001ncr and AX800134 accurately diagnosed HBV-positive HCC (AUC values of 0.9494 and 0.9491 for the training and validation cohorts, respectively). The diagnostic performance of the panel remained high in patients with AFP≤400 ng/ml (AUC values of 0.9371 and 0.9527 for the training and validation cohorts, respectively). The panel also diagnosed early HCC (AUC values of 0.9450 and 0.9564 for the training and validation cohorts, respectively).

conclusionOur results indicated that the serum expression of uc001ncr and AX800134 has potential as novel potential biomarker for the diagnosis of HCC, especially in patients with AFP≤400 ng/ml or early-stage disease (BCLC 0+A).

Indexed as

TranscriptomeBiomarkers, TumorCarcinoma, HepatocellularCase-Control StudiesCluster AnalysisFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHepatitis B, ChronicHumansLiver NeoplasmsMalePrognosisReproducibility of ResultsRNA, Long NoncodingROC CurveBiomarkers, TumorRNA, Long Noncoding

Identifiers

PMID26674525
PMCPMC4684503
OpenAlexW2220559134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.